Switzerland
· Delayed Price · Currency is CHF Basilea Pharmaceutica AG Company Description
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives.
The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.
It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia.
Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials.
Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.
| Country | Switzerland |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 147 |
| CEO | David Veitch |
Contact Details
Address: Hegenheimermattweg 167b Allschwil, 4123 Switzerland | |
| Phone | 41 61 606 11 11 |
| Website | basilea.com |
Stock Details
| Ticker Symbol | BSLN |
| Exchange | SIX Swiss Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CHF |
| ISIN Number | CH0011432447 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| David Veitch | Chief Executive Officer |
| Adesh Kaul | Chief Financial Officer |
| Dr. Gerrit Hauck Ph.D. | Chief Technology Officer |
| Dr. Laurenz Kellenberger Ph.D. | Chief Scientific Officer |
| Dr. Marc Engelhardt M.D. | Chief Medical Officer |
| Dr. Peer Nils Schroder | Head of Corporate Communications and Investor Relations |
| Damian Heller | General Counsel and Corporate Secretary |
| Andreas Kumin | Head of Corporate Development |
| Ursula Eberhardt | Head of Global Human Resources |
| Mark Jones Ph.D. | Head of Global Affairs |